Genentech pays $300m for preclinical Alzheimer antibody licence
Geneva – Genentech and the Swiss biotech start-up AC Immune have entered into a Global Licence Agreement for the development of anti-beta-amyloid antibodies for the treatment of Alzheimer’s disease. Under the terms of the agreement, Genentech makes an undisclosed upfront payment to AC Immune with the potential for a total of over US-$300 million including milestones. “The terms of the deal will provide AC Immune with a solid financial basis beyond the next three years”, said Dr. Armin Mäder, CFO of AC Immune. AC Immune has used its SupraAntigen technology to develop conformation-specific antibodies that target the beta-sheet peptides and induce a structural transition to alpha-helical proteins. For Genentech, the deal represents one of the first steps towards adding CNS diseases to the traditional fields of oncology and immunology.